CLASS II ONGOING Drug recall · Reported 1 Mar 2023 · FDA Enforcement Report

Tacrolimus Capsules, USP, 5 mg recalled by Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is recalling Tacrolimus Capsules, USP, 5 mg, distributed nationwide in the US. The recall was initiated on 8 Feb 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # C2106445; Exp. 03/2024
NDC55111-525, 55111-526, 55111-527
UPC0355111527015, 0355111525011, 0355111526018
Quantity recalled4,320 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0330-2023
FDA event ID
91661
Recalling firm
Dr. Reddy's Laboratories, Princeton, NJ
Manufacturer
Dr. Reddy's Laboratories Limited
Classification
Class II
Status
Ongoing
Recall initiated
8 Feb 2023
FDA classified
21 Feb 2023
Reported
1 Mar 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

8 Feb 2023Recall initiated by company
21 Feb 2023Classified by FDA+13 days
1 Mar 2023Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Product as listed by the FDA

Tacrolimus Capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Mfd. by Dr. Reddy's Laboratories Limited, Bachupally - 500 090, INDIA; NDC 55111-525-01.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Tacrolimus Capsules, USP, 5 mg recalled?

Yes. Dr. Reddy's Laboratories recalled Tacrolimus Capsules, USP, 5 mg on 8 Feb 2023. The recall is Class II and its status is Ongoing. Recall number D-0330-2023.

Why was it recalled?

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Which lots are affected?

Lot # C2106445; Exp. 03/2024

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Dr. Reddy's Laboratories

All 165

Other Tacrolimus recalls

All 10